Samvedna Samvedn, Jindal Shammy, Mishra Gaurav, Madan Jyotsana R, Gupta Gaurav, Awasthi Rajendra, Pinto Terezinha De Jesus Andreoli, Dua Kamal, Kulkarni Giriraj T
Laureate Institute of Pharmacy, Jawalamukhi, India.
Drug Delivery and Nanotechnology Laboratory, Bhagyoday Teerth Pharmacy College, Sagar, India.
Polim Med. 2018 Jan-Jun;48(1):31-40. doi: 10.17219/pim/99951.
Levocetirizine, active R (-) enantiomer of cetirizine, is an orally active and selective H1 receptor antagonist used medically as an anti-allergic. Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation mediated by immunoglobulin E (IgE) in the membrane lining the nose after allergen exposure.
The purpose of the present study was to prepare rapidly disintegrating tablets of levocetirizine after its complexation with β-cyclodextrin (β-CD).
Levocetirizine-β-CD complex tablets were prepared by direct compression technique using 3 synthetic superdisintegrants in different proportions. Development of the formulation in the present study was mainly based on the concentration of superdisintegrants and the properties of the drug. Nine batches of tablets were formulated and evaluated for various parameters: drug content, weight variation, water absorption ratio, wetting time, in vitro disintegration, hardness, friability, thickness uniformity, and in vitro dissolution.
A Fourier-transform infrared spectroscopy (FTIR) study showed that there were no significant interactions between the drug and the excipients. The prepared tablets were good in appearance and showed acceptable results for hardness and friability. The in vitro disintegrating time of the formulated tablet batches was found to be 15-35 s percentage and the drug content of tablets in all formulations was found to be between 90-102%, which complied with the limits established in the United States Pharmacopeia.
Complexation of levocetirizine with β-CD significantly improves the solubility of the drug. The disintegration time of the tablets was decreased with an increase in superdisintegrant amount. The tablets (batch CPX5) had a minimum disintegration time of 20 s and 99.99% of the drug was released within 10 min.
左西替利嗪是西替利嗪的活性R(-)对映体,是一种口服活性选择性H1受体拮抗剂,医学上用作抗过敏药。过敏性鼻炎是一种在过敏原暴露后,由鼻腔内膜中免疫球蛋白E(IgE)介导的炎症引起的鼻部症状性疾病。
本研究的目的是在左西替利嗪与β-环糊精(β-CD)络合后制备其快速崩解片。
采用直接压片技术,使用3种不同比例的合成超级崩解剂制备左西替利嗪-β-CD复方片。本研究中制剂的开发主要基于超级崩解剂的浓度和药物的性质。制备了9批片剂,并对各种参数进行了评估:药物含量、重量差异、吸水率、润湿时间、体外崩解、硬度、脆碎度、厚度均匀性和体外溶出度。
傅里叶变换红外光谱(FTIR)研究表明,药物与辅料之间没有显著相互作用。制备的片剂外观良好,硬度和脆碎度结果可接受。所制备片剂批次的体外崩解时间为15 - 35秒,所有制剂中片剂的药物含量在90% - 102%之间,符合美国药典规定的限度。
左西替利嗪与β-CD络合显著提高了药物的溶解度。片剂的崩解时间随着超级崩解剂用量的增加而缩短。片剂(批次CPX5)的最短崩解时间为20秒,99.99%的药物在10分钟内释放。